|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2.
|
Hayat MJ, Howlader N, Reichman ME and
Edwards BK: Cancer statistics, trends, and multiple primary cancer
analyses from the Surveillance, Epidemiology, and End Results
(SEER) Program. Oncologist. 12:20–37. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Luce JK: Chemotherapy of malignant
melanoma. Cancer. 30:1604–1615. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Benjamin RS: Chemotherapy of malignant
melanoma. World J Surg. 3:321–328. 1979. View Article : Google Scholar
|
|
5.
|
Huncharek M, Caubet JF and McGarry R:
Single-agent DTIC versus combination chemotherapy with or without
immunotherapy in metastatic melanoma: a meta-analysis of 3273
patients from 20 randomized trials. Melanoma Res. 11:75–81. 2001.
View Article : Google Scholar
|
|
6.
|
Legha SS, Ring S, Papadopoulos N, Plager C
and Benjamin R: A prospective evaluation of a triple-drug regimen
containing cisplatin, vinblastine, and dacarbazine (CVD) for
metastatic melanoma. Cancer. 64:2024–2029. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Atkins MB, Hsu J, Lee S, et al: Phase III
trial comparing concurrent biochemotherapy with cisplatin,
vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b
with cisplatin, vinblastine, and dacarbazine alone in patients with
metastatic malignant melanoma (E3695): a trial coordinated by the
Eastern Cooperative Oncology Group. J Clin Oncol. 26:5748–5754.
2008.
|
|
8.
|
Chapman PB, Einhorn LH, Meyers ML, et al:
Phase III multi-center randomized trial of the Dartmouth regimen
versus dacarbazine in patients with metastatic melanoma. J Clin
Oncol. 17:2745–2751. 1999.PubMed/NCBI
|
|
9.
|
Lewis MG: Possible immunological factors
in human malignant melanoma in Uganda. Lancet. 2:921–922. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Tefany FJ, Barnetson RS, Halliday GM,
McCarthy SW and McCarthy WH: Immunocytochemical analysis of the
cellular infiltrate in primary regressing and non-regressing
malignant melanoma. J Inves Dermatol. 97:197–202. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ram M and Shoenfeld Y: Harnessing
autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N
Y Acad Sci. 1110:410–425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Merimsky O, Shoenfeld Y and Fishman P: The
clinical significance of antityrosinase antibodies in melanoma and
related hypopigmentary lesions. Clin Rev Allergy Immunol.
16:227–236. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Fishman P, Azizi E, Shoenfeld Y, et al:
Vitiligo autoantibodies are effective against melanoma. Cancer.
72:2365–2369. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Atkins MB, Lotze MT, Dutcher JP, et al:
High-dose recombinant interleukin 2 therapy for patients with
metastatic melanoma: analysis of 270 patients treated between 1985
and 1993. J Clin Oncol. 17:2105–2116. 1999.PubMed/NCBI
|
|
15.
|
Komenaka I, Hoerig H and Kaufman HL:
Immunotherapy for melanoma. Clin Dermatol. 22:251–265. 2004.
View Article : Google Scholar
|
|
16.
|
Hodi FS, O’Day SJ, McDermott DF, et al:
Improved survival with ipilimumab in patients with metastatic
melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar
|
|
17.
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sosman JA, Kim KB, Schuchter L, et al:
Survival in BRAF V600-mutant advanced melanoma treated with
vemurafenib. N Engl J Med. 366:707–714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Chapman PB, Hauschild A, Robert C, et al:
Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Curtin JA, Busam K, Pinkel D and Bastian
BC: Somatic activation of KIT in distinct subtypes of melanoma. J
Clin Oncol. 24:4340–4346. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hodi FS, Friedlander P, Corless CL, et al:
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin
Oncol. 26:2046–2051. 2008. View Article : Google Scholar : PubMed/NCBI
|
